Boston-based drug Surface Logix announced today that Keith Dionne taken the reins as president and CEO of the privately held developer of small-molecule drugs. Dionne was previously CEO of Alantos Pharmaceuticals, which was acquired by by Amgen for some $300 million; he also spent 7 years in various roles at Cambridge, MA-based Millennium Pharmaceuticals.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
